Ellodi Pharmaceuticals Welcomes Debra Silberg MD, PhD, FACG to its Board of Directors
Accomplished Life Sciences Executive and Academic Joins Board Blue Bell, PA – February 27, 2023 – Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company dedicated to the continued development of APT-1011, a novel, investigational oral therapy for the treatment of Eosinophilic Esophagitis (EoE), announced today that Debra Silberg, MD, PhD, FACG has joined the company’s board […]
Ellodi Pharmaceuticals Announces Fast Track Designation Granted by the FDA to APT-1011 for the Treatment of Eosinophilic Esophagitis (EoE)
Lawrenceville, N.J. – February 8, 2021 – Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company, today announced that APT-1011 (fluticasone propionate oral disintegrating tablet) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of Eosinophilic Esophagitis (EoE), a rare, chronic allergic inflammatory disease characterized by eosinophilic infiltration of […]
Ellodi Pharmaceuticals Announces Phase 2b Data Presented at ACG 2020 on the Safety and Efficacy of Maintenance Treatment Following Induction of Remission in Eosinophilic Esophagitis with APT-1011
The abstract received ACG’s Category Award (Esophagus) Lawrenceville, N.J. – October 27, 2020 – Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company, today announced an oral presentation by Professor Evan Dellon M.D., M.P.H, at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting and Postgraduate Course, highlighting the results of APT-1011 (fluticasone propionate oral disintegrating […]
Ellodi Pharmaceuticals Welcomes Dr. David Kessler and John Fraher to its Board of Directors
Accomplished life sciences executives join inaugural board of the newly formed company Lawrenceville, N.J. – October 21, 2020 – Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company formed by TPG Capital, today announced that David Kessler, M.D., and John Fraher have joined the company’s newly established Board of Directors. Dr. Kessler and Fraher will serve on […]
TPG Forms Ellodi Pharmaceuticals to Continue Clinical Development of APT-1011 for Treatment of Eosinophilic Esophagitis
TPG Capital establishes new entity to continue the development of select clinical assets spun-out of Adare Pharmaceuticals Announcement follows TPG Capital’s sale of Adare Pharmaceuticals’ specialty CDMO pharmaceutical technology and microbiome businesses San Francisco and Fort Worth, Texas –September 22, 2020 – TPG Capital, the private equity platform of alternative asset firm TPG, announced today that […]
Primary End-Point achieved in Phase IIb Study (FLUTE™) for APT-1011
Princeton, New Jersey – March 12, 2019 Adare Pharmaceuticals (Adare) today announced positive results from its Phase IIb study (FLUTE™) for one of its rare disease investigational products, APT-1011 (AdvaTab® Fluticasone) for Eosinophilic Esophagitis (EoE). Eosinophilic Esophagitis (EoE) is a chronic, allergic inflammatory disease characterized by eosinophilic infiltration of the esophagus, which can lead to […]
